Insulin-like growth factor-I (IGF-I) acts as an important mediator between growth hormone and growth throughout fetal and childhood development. More circumstantial evidence indicates the association of IGF-I to the risk of cancer. High concentrations of IGF-I has been shown to be an increased risk of colorectal cancer and breast cancer in some studies and less consistently with prostate, thyroid, and haematological malignancies. IGF-I is a potent mitogen and important stimulus for adipocyte differentiation. IGF-I can reduce hyperglycemia in patients with severe insulin resistance by direct effects mediated via the IGF-I receptor. IGF-I infusion lowers insulin and lipid levels in healthy humans and reduces plasma leptin concentrations in rats, suggesting that IGF-I may reduce the degree of insulin resistance in type 2 diabetes, obesity, and hyperlipidemia.
 
Detection Range:
    16 - 1000 pg/mL
Sensitivity:
    8 pg/mL